Corporate Actions
Material events companies report to the SEC on Form 8-K: mergers, dividends, buybacks, splits, management changes, bankruptcies and more. Enter a ticker for one company's history, or browse the latest across the market.
MoonLake Immunotherapeutics (MLTX)
1 8-K filing| Filed | Action | What the filing says | SEC |
|---|---|---|---|
| Feb 23, 2026 |
Management Change
Item 1.01Item 2.02Item 2.03Item 5.02Item 7.01Item 8.01Item 9.01
|
Entry into a Material Definitive Agreement On February 20, 2026 (the “Amendment Closing Date”), MoonLake Immunotherapeutics (the “Company”), as a guarantor, entered into a first amendment to loan and security agreement…Entry into a Material Definitive Agreement On February 20, 2026 (the “Amendment Closing Date”), MoonLake Immunotherapeutics (the “Company”), as a guarantor, entered into a first amendment to loan and security agreement (the loan and security agreement, as so amended, the “Amended Loan and Security Agreement”) with its subsidiary, MoonLake Immunotherapeutics AG, as borrower, the other guarantors party thereto, the lenders party thereto (the “Lenders”), and Hercules Capital, Inc., as the administrative agent and collateral agent (the “Agent”) for itself and the Lenders, pursuant to which the parties agreed to amend the loan and security agreement dated March 31, 2025 to, among other things, modify the available tranches, milestone dates and financial covenants. As described below, after giving effect to a $25.0 million draw on the Amendment Closing Date, the remaining tranches under the A |
Filing 8-K |
Each 8-K is classified by its most significant item; hover an item number for its title. Classification and excerpts are read automatically and can be wrong; the filing on SEC.gov is the authority. For research, not investment advice.